U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Metastatic Lung Non-Small Cell Squamous Carcinoma

MedGen UID:
1679728
•Concept ID:
C4763570
•
Neoplastic Process
Synonyms: Metastatic Non-Small Cell Squamous Lung Carcinoma; Metastatic Squamous Non-Small Cell Lung Carcinoma

Definition

A squamous non-small cell carcinoma that arises from the lung and has metastasized to another anatomic site. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVMetastatic Lung Non-Small Cell Squamous Carcinoma

Professional guidelines

PubMed

PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review.
Brody R, Zhang Y, Ballas M, Siddiqui MK, Gupta P, Barker C, Midha A, Walker J
Lung Cancer 2017 Oct;112:200-215. Epub 2017 Aug 10 doi: 10.1016/j.lungcan.2017.08.005. PMID: 29191596
Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.
Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA
Mayo Clin Proc 2008 May;83(5):584-94. doi: 10.4065/83.5.584. PMID: 18452692Free PMC Article
Lung cancer: diagnosis and management.
Collins LG, Haines C, Perkel R, Enck RE
Am Fam Physician 2007 Jan 1;75(1):56-63. PMID: 17225705

Recent clinical studies

Etiology

Metastatic potential of T1a and T1b non-small cell lung cancer: analysis in the Czech population.
Tulinský L, Kepičová M, Mitták M, Martínek L
Rozhl Chir 2023;102(6):244-250. doi: 10.33699/PIS.2023.102.6.244-250. PMID: 38286653
Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial.
Makharadze T, Gogishvili M, Melkadze T, Baramidze A, Giorgadze D, Penkov K, Laktionov K, Nemsadze G, Nechaeva M, Rozhkova I, Kalinka E, Li S, Li Y, Kaul M, Quek RGW, Pouliot JF, Seebach F, Lowy I, Gullo G, Rietschel P
J Thorac Oncol 2023 Jun;18(6):755-768. Epub 2023 Mar 29 doi: 10.1016/j.jtho.2023.03.008. PMID: 37001859
Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial.
Gettinger SN, Redman MW, Bazhenova L, Hirsch FR, Mack PC, Schwartz LH, Bradley JD, Stinchcombe TE, Leighl NB, Ramalingam SS, Tavernier SS, Yu H, Unger JM, Minichiello K, Highleyman L, Papadimitrakopoulou VA, Kelly K, Gandara DR, Herbst RS
JAMA Oncol 2021 Sep 1;7(9):1368-1377. doi: 10.1001/jamaoncol.2021.2209. PMID: 34264316Free PMC Article
Histologic transformation of non-small-cell lung cancer in brain metastases.
Jiang M, Zhu X, Han X, Jing H, Han T, Li Q, Ding X
Int J Clin Oncol 2019 Apr;24(4):375-384. Epub 2018 Nov 16 doi: 10.1007/s10147-018-1369-1. PMID: 30443811
Innovative Clinical Trials: The LUNG-MAP Study.
Steuer CE, Papadimitrakopoulou V, Herbst RS, Redman MW, Hirsch FR, Mack PC, Ramalingam SS, Gandara DR
Clin Pharmacol Ther 2015 May;97(5):488-91. doi: 10.1002/cpt.88. PMID: 25676724

Diagnosis

Non-small cell lung carcinomas with diffuse coexpression of TTF1 and p40: clinicopathological and genomic features of 14 rare biphenotypic tumours.
Savari O, Febres-Aldana C, Chang JC, Fanaroff RE, Ventura K, Bodd F, Paik P, Vundavalli M, Saqi A, Askin FB, Travis WD, Rekhtman N
Histopathology 2023 Jan;82(2):242-253. Epub 2022 Oct 20 doi: 10.1111/his.14801. PMID: 36130728Free PMC Article
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.
Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, Ponce S, Ares LP, Leroy L, Audigier-Valette C, Felip E, Zerón-Medina J, Garrido P, Brosseau S, Zalcman G, Mazieres J, Caramela C, Lahmar J, Adam J, Chaput N, Soria JC, Besse B
JAMA Oncol 2018 Mar 1;4(3):351-357. doi: 10.1001/jamaoncol.2017.4771. PMID: 29327044Free PMC Article
Progress and prospects of early detection in lung cancer.
Blandin Knight S, Crosbie PA, Balata H, Chudziak J, Hussell T, Dive C
Open Biol 2017 Sep;7(9) doi: 10.1098/rsob.170070. PMID: 28878044Free PMC Article
Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study.
Cagney DN, Martin AM, Catalano PJ, Redig AJ, Lin NU, Lee EQ, Wen PY, Dunn IF, Bi WL, Weiss SE, Haas-Kogan DA, Alexander BM, Aizer AA
Neuro Oncol 2017 Oct 19;19(11):1511-1521. doi: 10.1093/neuonc/nox077. PMID: 28444227Free PMC Article
Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.
Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA
Mayo Clin Proc 2008 May;83(5):584-94. doi: 10.4065/83.5.584. PMID: 18452692Free PMC Article

Therapy

Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study.
Novello S, Kowalski DM, Luft A, Gümüş M, Vicente D, Mazières J, Rodríguez-Cid J, Tafreshi A, Cheng Y, Lee KH, Golf A, Sugawara S, Robinson AG, Halmos B, Jensen E, Schwarzenberger P, Pietanza MC, Paz-Ares L
J Clin Oncol 2023 Apr 10;41(11):1999-2006. Epub 2023 Feb 3 doi: 10.1200/JCO.22.01990. PMID: 36735893Free PMC Article
Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3).
Shi Y, Wu L, Yu X, Xing P, Wang Y, Zhou J, Wang A, Shi J, Hu Y, Wang Z, An G, Fang Y, Sun S, Zhou C, Wang C, Ye F, Li X, Wang J, Wang M, Liu Y, Zhao Y, Yuan Y, Feng J, Chen Z, Shi J, Sun T, Wu G, Shu Y, Guo Q, Zhang Y, Song Y, Zhang S, Chen Y, Li W, Niu H, Hu W, Wang L, Huang J, Zhang Y, Cheng Y, Wu Z, Peng B, Sun J, Mancao C, Wang Y, Sun L
Cancer Commun (Lond) 2022 Dec;42(12):1314-1330. Epub 2022 Nov 6 doi: 10.1002/cac2.12385. PMID: 36336841Free PMC Article
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.
Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, Morise M, Felip E, Andric Z, Geater S, Özgüroğlu M, Zou W, Sandler A, Enquist I, Komatsubara K, Deng Y, Kuriki H, Wen X, McCleland M, Mocci S, Jassem J, Spigel DR
N Engl J Med 2020 Oct 1;383(14):1328-1339. doi: 10.1056/NEJMoa1917346. PMID: 32997907
A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407.
Paz-Ares L, Vicente D, Tafreshi A, Robinson A, Soto Parra H, Mazières J, Hermes B, Cicin I, Medgyasszay B, Rodríguez-Cid J, Okamoto I, Lee S, Ramlau R, Vladimirov V, Cheng Y, Deng X, Zhang Y, Bas T, Piperdi B, Halmos B
J Thorac Oncol 2020 Oct;15(10):1657-1669. Epub 2020 Jun 26 doi: 10.1016/j.jtho.2020.06.015. PMID: 32599071
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, Bogart J, Hu C, Forster K, Magliocco A, Kavadi V, Garces YI, Narayan S, Iyengar P, Robinson C, Wynn RB, Koprowski C, Meng J, Beitler J, Gaur R, Curran W Jr, Choy H
Lancet Oncol 2015 Feb;16(2):187-99. Epub 2015 Jan 16 doi: 10.1016/S1470-2045(14)71207-0. PMID: 25601342Free PMC Article

Prognosis

Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial.
Makharadze T, Gogishvili M, Melkadze T, Baramidze A, Giorgadze D, Penkov K, Laktionov K, Nemsadze G, Nechaeva M, Rozhkova I, Kalinka E, Li S, Li Y, Kaul M, Quek RGW, Pouliot JF, Seebach F, Lowy I, Gullo G, Rietschel P
J Thorac Oncol 2023 Jun;18(6):755-768. Epub 2023 Mar 29 doi: 10.1016/j.jtho.2023.03.008. PMID: 37001859
Construction and Validation of Prognosis Nomogram for Metastatic Lung Squamous Cell Carcinoma: A Population-Based Study.
Liu Y, Sun M, Xiong Y, Gu X, Zhang K, Liu L
Technol Cancer Res Treat 2022 Jan-Dec;21:15330338221132035. doi: 10.1177/15330338221132035. PMID: 36217877Free PMC Article
CCDC85B promotes non-small cell lung cancer cell proliferation and invasion.
Feng Y, Gao Y, Yu J, Jiang G, Zhang X, Lin X, Han Q, Rong X, Xu H, Li Q, Qiu X, Wang E
Mol Carcinog 2019 Jan;58(1):126-134. Epub 2018 Oct 9 doi: 10.1002/mc.22914. PMID: 30242906
Surgical treatment in non-small cell lung cancer with pulmonary oligometastasis.
He J, Li Y, An J, Hu L, Zhang J
World J Surg Oncol 2017 Feb 2;15(1):36. doi: 10.1186/s12957-017-1105-8. PMID: 28148271Free PMC Article
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, Bogart J, Hu C, Forster K, Magliocco A, Kavadi V, Garces YI, Narayan S, Iyengar P, Robinson C, Wynn RB, Koprowski C, Meng J, Beitler J, Gaur R, Curran W Jr, Choy H
Lancet Oncol 2015 Feb;16(2):187-99. Epub 2015 Jan 16 doi: 10.1016/S1470-2045(14)71207-0. PMID: 25601342Free PMC Article

Clinical prediction guides

PTEN Loss Confers Resistance to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells.
Exposito F, Redrado M, Houry M, Hastings K, Molero-Abraham M, Lozano T, Solorzano JL, Sanz-Ortega J, Adradas V, Amat R, Redin E, Leon S, Legarra N, Garcia J, Serrano D, Valencia K, Robles-Oteiza C, Foggetti G, Otegui N, Felip E, Lasarte JJ, Paz-Ares L, Zugazagoitia J, Politi K, Montuenga L, Calvo A
Cancer Res 2023 Aug 1;83(15):2513-2526. doi: 10.1158/0008-5472.CAN-22-3023. PMID: 37311042
Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3).
Shi Y, Wu L, Yu X, Xing P, Wang Y, Zhou J, Wang A, Shi J, Hu Y, Wang Z, An G, Fang Y, Sun S, Zhou C, Wang C, Ye F, Li X, Wang J, Wang M, Liu Y, Zhao Y, Yuan Y, Feng J, Chen Z, Shi J, Sun T, Wu G, Shu Y, Guo Q, Zhang Y, Song Y, Zhang S, Chen Y, Li W, Niu H, Hu W, Wang L, Huang J, Zhang Y, Cheng Y, Wu Z, Peng B, Sun J, Mancao C, Wang Y, Sun L
Cancer Commun (Lond) 2022 Dec;42(12):1314-1330. Epub 2022 Nov 6 doi: 10.1002/cac2.12385. PMID: 36336841Free PMC Article
Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial.
Gettinger SN, Redman MW, Bazhenova L, Hirsch FR, Mack PC, Schwartz LH, Bradley JD, Stinchcombe TE, Leighl NB, Ramalingam SS, Tavernier SS, Yu H, Unger JM, Minichiello K, Highleyman L, Papadimitrakopoulou VA, Kelly K, Gandara DR, Herbst RS
JAMA Oncol 2021 Sep 1;7(9):1368-1377. doi: 10.1001/jamaoncol.2021.2209. PMID: 34264316Free PMC Article
Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
Wang J, Lu S, Yu X, Hu Y, Sun Y, Wang Z, Zhao J, Yu Y, Hu C, Yang K, Feng G, Ying K, Zhuang W, Zhou J, Wu J, Leaw SJ, Zhang J, Lin X, Liang L, Yang N
JAMA Oncol 2021 May 1;7(5):709-717. doi: 10.1001/jamaoncol.2021.0366. PMID: 33792623Free PMC Article
A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753).
Waqar SN, Redman MW, Arnold SM, Hirsch FR, Mack PC, Schwartz LH, Gandara DR, Stinchcombe TE, Leighl NB, Ramalingam SS, Tanna SH, Raddin RS, Minichiello K, Bradley JD, Kelly K, Herbst RS, Papadimitrakopoulou VA
Clin Lung Cancer 2021 May;22(3):170-177. Epub 2020 Oct 14 doi: 10.1016/j.cllc.2020.09.013. PMID: 33221175Free PMC Article

Recent systematic reviews

The safety and efficacy of tislelizumab, alone or in combination with chemotherapy, for the treatment of non-small cell lung cancer: a systematic review of clinical trials.
Daei Sorkhabi A, ZareDini M, Fazlollahi A, Sarkesh A, Naseri A, Mousavi SE, Nejadghaderi SA, Sullman MJM, Kolahi AA, Safiri S
BMC Pulm Med 2023 Dec 8;23(1):495. doi: 10.1186/s12890-023-02755-3. PMID: 38066549Free PMC Article
Identifying optimal first-line immune checkpoint inhibitors based regiments for advanced non-small cell lung cancer without oncogenic driver mutations: A systematic review and network meta-analysis.
Liu T, Wu S, Fang W, Li H, Su L, Qi G, Li H, Liu Y
PLoS One 2023;18(4):e0283719. Epub 2023 Apr 18 doi: 10.1371/journal.pone.0283719. PMID: 37071610Free PMC Article
Association between time-to-treatment and outcomes in non-small cell lung cancer: a systematic review.
Hall H, Tocock A, Burdett S, Fisher D, Ricketts WM, Robson J, Round T, Gorolay S, MacArthur E, Chung D, Janes SM, Peake MD, Navani N
Thorax 2022 Aug;77(8):762-768. Epub 2021 Aug 17 doi: 10.1136/thoraxjnl-2021-216865. PMID: 34404753Free PMC Article
Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
Dafni U, Tsourti Z, Vervita K, Peters S
Lung Cancer 2019 Aug;134:127-140. Epub 2019 May 30 doi: 10.1016/j.lungcan.2019.05.029. PMID: 31319971
PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review.
Brody R, Zhang Y, Ballas M, Siddiqui MK, Gupta P, Barker C, Midha A, Walker J
Lung Cancer 2017 Oct;112:200-215. Epub 2017 Aug 10 doi: 10.1016/j.lungcan.2017.08.005. PMID: 29191596

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...